Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
41.21B
Market cap41.21B
Price-Earnings ratio
74.32
Price-Earnings ratio74.32
Dividend yield
Dividend yield
Average volume
1.62M
Average volume1.62M
High today
$322.49
High today$322.49
Low today
$306.03
Low today$306.03
Open price
$314.71
Open price$314.71
Volume
369.93K
Volume369.93K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$273.11
52 Week low$273.11

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $308.64. The company's market cap stands at 41.21B, with a P/E ratio of 74.32.

On 2026-07-10, Alnylam Pharmaceuticals(ALNY) stock traded between a low of $306.03 and a high of $322.49. Shares are currently priced at $308.64, which is +0.9% above the low and -4.3% below the high.

Alnylam Pharmaceuticals(ALNY) shares are trading with a volume of 369.93K, against a daily average of 1.62M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $273.11.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $273.11.

ALNY News

Simply Wall St 2h
Alnylam Pharmaceuticals Could Be 28% Undervalued Following Rival ATTR Trial Failure

Advertisement Why Alnylam Pharmaceuticals Stock Is Back in Focus Alnylam Pharmaceuticals (ALNY) moved sharply higher after a late stage trial for a competing...

Alnylam Pharmaceuticals Could Be 28% Undervalued Following Rival ATTR Trial Failure
TipRanks 2h
Alnylam price target raised to $400 from $370 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Alnylam (ALNY) to $400 from $370 and keeps an Equal Weight rating on the shares. TipRanks has entered a new ar...

The Wall Street Journal 4h
Health Care Roundup: Market Talk

Yves Herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk

Analyst ratings

73%

of 30 ratings
Buy
73.3%
Hold
26.7%
Sell
0%

More ALNY News

Nasdaq 22h
Nasdaq 100 Movers: PEP, ALNY

In early trading on Thursday, shares of Alnylam Pharmaceuticals topped the list of the day's best performing components of the Nasdaq 100 index, trading up 15.4...

Nasdaq 100 Movers: PEP, ALNY
TipRanks 23h
Alnylam price target raised to $468 from $420 at Raymond James

Raymond James raised the firm’s price target on Alnylam (ALNY) to $468 from $420 and keeps an Outperform rating on the shares. Ionis’ (IONS) failed Phase 3 ATTR...

Investing.com 24h
Why is Alnylam Pharmaceuticals stock surging today? - Investing.com

...

Why is Alnylam Pharmaceuticals stock surging today? - Investing.com

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.